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Juan José Gómez-Doblas, Javier Muñiz, Joaquín J. Alonso Martín, Eulalia Roig 
To the Editor, 
We appreciate the interest shown by Vidal-Pérez et al. in our article published recently in Revista 
Española de Cardiología,1 which provides us with an opportunity to present some interesting additional 
information not included in the article itself. We agree on the importance of knowing the thromboembolic 
risk of the population included in the OFRECE study, both for patients with a diagnosis of atrial 
fibrillation and for the general population. In our study, the mean (standard deviation) CHADS2 and 
CHAD2DS2-VASc of patients with atrial fibrillation was 2.3 (1.3) and 3.8 (1.6), respectively. In the 
general population, the mean (standard deviation) CHADS2 and CHAD2DS2-VASc of patients with atrial 
fibrillation was 0.8 (1) and 1.8 (1.5), respectively. The distribution of both scales is in agreement with that 
of the Val-FAAP and AFABE studies,2, 3 although the similarity is greater in the 2 population-based 
studies (Figure). These data are, we believe, relevant because they show that the level of risk in the 
population with atrial fibrillation is very similar to that of the populations included in clinical trials with 
new oral anticoagulants. In addition, an increasing body of evidence suggests that thromboembolic risk, 
as measured with these scales in the population without a diagnosis of atrial fibrillation, is associated with 




Figure. Prevalences by thromboembolic risk scales in the OFRECE, AFABE, and Val-FAAP studies. 
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